# Probiotics Gas Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/probiotics-gas-meta-analysis-evidence-review
Category: evidence-review
Summary: Probiotics Gas Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic
Last reviewed: 2026-07-04
Reviewed by: Migaku Evidence Review
# Probiotics Gas Meta-analysis: What the Evidence Says

## Quick Answer

Probiotics Gas Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis | systematic review | 1 | 2026-04-22 | 10.1186/s12888-026-08097-8 |
| Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications | narrative review | 3 | 2026-03-17 | 10.1007/s10482-026-02278-x |

## What The Sources Report

- Evidence shows that MDD often involves impaired intestinal barrier function, chronic low-grade inflammation, and gut microbiota dysbiosis, all of which SCFAs closely modulate. [Li Jingchun (2026); evidence level 1]
- This inconsistency is evident not only in the association's direction but also in a component-specific pattern-some studies report significantly reduced propionate and butyrate levels in MDD patients, with no difference observed for acetate. [Li Jingchun (2026); evidence level 1]
- Strain Evidence strength Proposed Mechanism Lactobacillus acidophilus DDS-1 2016 Pakdaman et al. [Perets Tsachi Tsadok (2026); evidence level 3]
- Randomized, double-blind, placebo-controlled crossover trial reported reduced lactose intolerance symptom scores after supplementation, with improved tolerance to lactose challenge High beta-galactosidase (lactase) activity enhances lactose hydrolysis; may reduce colonic lactose load and gas production; potential modulation of gut microbiota Bifidobacterium animalis subsp. [Perets Tsachi Tsadok (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For probiotics gas meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Li Jingchun (2026). Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis. DOI: 10.1186/s12888-026-08097-8. PMCID: PMC13235195. PMID: 42021200. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13235195/
- Perets Tsachi Tsadok (2026). Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications. DOI: 10.1007/s10482-026-02278-x. PMCID: PMC12995986. PMID: 41843249. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12995986/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.